Horizon
Horizon, a UK company supplying research tools to genomics companies, has appointed two non-executive directors of the board.
Susan Galbraith (pictured) is Senior VP and Head of Oncology Innovative Medicines at AstraZeneca, while Susan Searle is the co-founder and former CEO of Imperial Innovations Group.
Galbraith trained as a clinical oncologist and has more than 20 years’ combined academic and industry experience. Before AstraZeneca, she worked at Bristol-Myers Squibb, where she was VP of Oncology and Clinical Biomarkers from 2008 to 2010. Galbraith’s work focuses on biomarker strategies, redesigning governance processes and North American and European diagnostic development.
Susan Searle has an entrepreneurial background, having founded Imperial Innovations Group, a technology venture capital business which under her leadership invested in bioscience companies Abingdon Health, Circassia, CellMedica, Psioxus and Respivert.
She has sat on the boards of many technology, engineering and healthcare companies, including the advisory board for the Technology Strategy Board’s Emerging Technologies group.